Accessibility Menu
Ultragenyx Pharmaceutical Stock Quote

Ultragenyx Pharmaceutical (NASDAQ: RARE)

$33.14
(-3.1%)
-1.05
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$33.14
Daily Change
(-3.1%) $1.05
Day's Range
$33.1 - $34.33
Previous Close
$33.14
Open
$34.05
Beta
1.11
Volume
934,492
Average Volume
1,669,418
Market Cap
3.3B
Market Cap / Employee
$34.19M
52wk Range
$25.81 - $56.38
Revenue
-
Gross Margin
0.80%
Dividend Yield
N/A
EPS
-$5.53
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ultragenyx Pharmaceutical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
RARE-39.51%-64.39%-18.66%-19%
S&P+15.06%+95.03%+14.29%+278%

Ultragenyx Pharmaceutical Company Info

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$166.50M13.2%
Gross Profit$134.88M15.4%
Gross Margin81.01%1.5%
Market Cap$3.44B-7.7%
Market Cap / Employee$2.66M0.0%
Employees1.3K1.4%
Net Income-$114.95M12.6%
EBITDA-$99.27M7.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$185.34M-61.9%
Accounts Receivable$124.46M17.4%
Inventory46.515.8%

Liabilities

Q2 2025YOY Change
Long Term Debt$807.28M-7.0%
Short Term Debt$75.63M29.0%

Ratios

Q2 2025YOY Change
Return On Assets-36.44%3.5%
Return On Invested Capital-41.42%-2.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$110.73M-40.2%
Operating Free Cash Flow-$108.27M-40.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book11.8311.1913.1123.63-2.95%
Price to Sales10.157.195.905.87-20.64%
Price to Tangible Book Value23.0628.23102.72-44.45-9.95%
Enterprise Value to EBITDA-45.41-38.21-28.97-40.0315.82%
Return on Equity-295.3%-214.5%-386.3%-182.6%-12.39%
Total Debt$912.50M$910.01M$889.70M$882.91M-4.71%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.